Labcorp Highlights Strategic Priorities Driving Durable Growth and Shareholder Value at 2026 Investor Day
Labcorp reaffirmed its full-year 2026 guidance and unveiled a long-term financial outlook through 2029 at its 2026 Investor Day. The reaffirmed 2026 guidance calls for Enterprise revenue of $14,710M-$14,827M (up 5.4%-6.3%), adjusted EPS of $18.10-$18.55, and free cash flow of $1,240M-$1,360M. Through 2029, management targets compound annual revenue growth of 5%-8%, adjusted EPS growth of 8.5%-11.5%, and adjusted operating margin expansion of 75-150 basis points, with free cash flow growth in line with adjusted earnings.
Key figures
- Guidance
- FY2026 reaffirmed: Enterprise revenue $14,710M-$14,827M (+5.4%-6.3%), adjusted EPS $18.10-$18.55, free cash flow $1,240M-$1,360M; through 2029: revenue CAGR 5%-8%, adjusted EPS CAGR 8.5%-11.5%, adjusted operating margin expansion 75-150 bps, FCF growth in line with adjusted EPS growth
- Fcf guidance low musd
- 1240
- Fcf guidance high musd
- 1360
- Adjusted eps guidance low
- 18.1
- Revenue cagr through 2029
- 5%-8%
- Adjusted eps guidance high
- 18.55
- Biopharma revenue 2025 musd
- 3098
- Diagnostics revenue 2025 musd
- 10876
- Adjusted eps cagr through 2029
- 8.5%-11.5%
- Enterprise revenue 2025 base musd
- 13952
- Enterprise revenue guidance low musd
- 14710
- Enterprise revenue guidance high musd
- 14827
- Adjusted operating margin expansion bps by 2029
- 75-150
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.